observed that approximately 45% of MSS CRCs and 65% of MSI-H CRCs had a higher Immunoscore, an effective indicator for CRC relapse prediction based on the expression of CD3+ and CD8+ T cells surrounding the tumour, which could achieve a favourable antitumour response, while the rest with a low Immunoscore may be unable to benefit from ICIs treatment (71). The gene discussed is CD8A; the disease is colorectal carcinoma.